- Report
- August 2026
- 160 Pages
Global
From €3030EUR$3,320USD£2,597GBP
€3788EUR$4,150USD£3,246GBP
- Report
- January 2026
- 160 Pages
Global
From €2884EUR$3,160USD£2,471GBP
€3605EUR$3,950USD£3,089GBP
- Report
- January 2026
- 160 Pages
Global
From €2884EUR$3,160USD£2,471GBP
€3605EUR$3,950USD£3,089GBP
- Report
- October 2025
- 160 Pages
Global
From €2884EUR$3,160USD£2,471GBP
€3605EUR$3,950USD£3,089GBP
- Report
- October 2025
- 160 Pages
Global
From €2884EUR$3,160USD£2,471GBP
€3605EUR$3,950USD£3,089GBP
- Report
- April 2026
- 126 Pages
Global
From €3500EUR$4,108USD£3,104GBP
- Report
- July 2026
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- December 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- October 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- October 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- October 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- October 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- October 2025
- 150 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- May 2026
- 134 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- February 2026
- 139 Pages
Global
From €4427EUR$4,850USD£3,793GBP
- Report
- November 2025
- 193 Pages
Global
From €4518EUR$4,950USD£3,871GBP
- Report
- October 2025
- 83 Pages
Global
From €4107EUR$4,500USD£3,519GBP
From €5431EUR$5,950USD£4,654GBP
- Report
- December 2022
- 325 Pages
Global
From €4771EUR$5,410USD£3,950GBP
- Report
- September 2025
- 447 Pages
Global
From €4518EUR$4,950USD£3,871GBP

The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments.
The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market.
Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more